These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20629201)

  • 21. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate.
    Smith P; Bullock JM; Booker BM; Haas CE; Berenson CS; Jusko WJ
    Pharmacotherapy; 2004 Nov; 24(11):1508-14. PubMed ID: 15537555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacokinetics of imatinib mesylate.
    Levêque D; Maloisel F
    In Vivo; 2005; 19(1):77-84. PubMed ID: 15796158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.
    Widmer N; Decosterd LA; Csajka C; Leyvraz S; Duchosal MA; Rosselet A; Rochat B; Eap CB; Henry H; Biollaz J; Buclin T
    Br J Clin Pharmacol; 2006 Jul; 62(1):97-112. PubMed ID: 16842382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers.
    Swart PJ; Krauwinkel WJ; Smulders RA; Smith NN
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):33-6. PubMed ID: 16867168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome.
    Beumer JH; Natale JJ; Lagattuta TF; Raptis A; Egorin MJ
    Pharmacotherapy; 2006 Jul; 26(7):903-7. PubMed ID: 16803422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.
    Grimm SW; Richtand NM; Winter HR; Stams KR; Reele SB
    Br J Clin Pharmacol; 2006 Jan; 61(1):58-69. PubMed ID: 16390352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
    Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
    Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioavailability of two oral formulations of loratadine 20 mg with concomitant ketoconazole: an open-label, randomized, two-period crossover comparison in healthy Mexican adult volunteers.
    Piñeyro-López A; Pineyro-Garza E; Torres-Alanís O; Reyes-Araiza R; Gómez Silva M; Wacksman N; Lujàn Rangel R; de Lago A; Trejo D; Gonzàlez-de la Parra M; Namur S
    Clin Ther; 2006 Jan; 28(1):110-5. PubMed ID: 16490584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules.
    Nikolova Z; Peng B; Hubert M; Sieberling M; Keller U; Ho YY; Schran H; Capdeville R
    Cancer Chemother Pharmacol; 2004 May; 53(5):433-8. PubMed ID: 15132131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolism and disposition of imatinib mesylate in healthy volunteers.
    Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G
    Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple oral dosing of ketoconazole influences pharmacokinetics of quinidine after intravenous and oral administration in beagle dogs.
    Kuroha M; Shirai Y; Shimoda M
    J Vet Pharmacol Ther; 2004 Oct; 27(5):355-9. PubMed ID: 15500574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study.
    Pappas P; Karavasilis V; Briasoulis E; Pavlidis N; Marselos M
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):358-60. PubMed ID: 15883819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple oral dosing of ketoconazole increases dog exposure to ivermectin.
    Hugnet C; Lespine A; Alvinerie M
    J Pharm Pharm Sci; 2007; 10(3):311-8. PubMed ID: 17727794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib.
    Bornhäuser M; Pursche S; Bonin M; Freiberg-Richter J; Jenke A; Illmer T; Ehninger G; Schleyer E
    J Clin Oncol; 2005 Jun; 23(16):3855-6; author reply 3857-8. PubMed ID: 15923584
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
    Peng B; Hayes M; Resta D; Racine-Poon A; Druker BJ; Talpaz M; Sawyers CL; Rosamilia M; Ford J; Lloyd P; Capdeville R
    J Clin Oncol; 2004 Mar; 22(5):935-42. PubMed ID: 14990650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-administration of ritonavir and primaquine decreases plasma concentration of primaquine: single- and multiple-dose study in the rats.
    Louisa M; Soetikno V; Nafrialdi ; Setiabudy R; Suyatna FD
    Acta Med Indones; 2012 Oct; 44(4):273-9. PubMed ID: 23314966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primaquine is lethal for intracellular but not extracellular Trypanosoma cruzi.
    McCabe RE
    J Parasitol; 1988 Oct; 74(5):748-53. PubMed ID: 3138394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs.
    Ishizuka M; Nagai S; Sakamoto KQ; Fujita S
    Xenobiotica; 2007 May; 37(5):503-13. PubMed ID: 17523053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic interaction between efavirenz and ketoconazole in rats.
    Saadeddin A; Peris JE
    Xenobiotica; 2009 Feb; 39(2):135-9. PubMed ID: 19255939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacokinetics of imatinib.
    Peng B; Lloyd P; Schran H
    Clin Pharmacokinet; 2005; 44(9):879-94. PubMed ID: 16122278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.